Effect of docetaxel combined cisplatin for treatment of non small - cell lung cancer

Abstract

Objective To observe the clinical efficacy and adverse effects of combination chemotherapy with docetaxel com- bined cisplafin in the treatment of Ⅲ～Ⅳ stage non small - cell lung cancer (NSCLC). Methods Thirty - two patients with Ⅲ- Ⅳ stage NSCLC were enrolled into this study and given treatment of docetaxel combined eisplatin 35 mg/m2 of docctaxel was injec- ted within one hour in the first and eighth day combined with injection of 25 mg/m2 cisplatin in first 3 days. 3 mg of granisetron were injected to prevent vomiting before combination chemotherapy. At least 2 courses were conducted with an interval of 28 days. Imageological examination was done and the diameters of tumor were measured to evaluate the effect of treatment and adverse effects. Results The total responsive rate was 40.63% (13/32), 2 of which were cure recovery(CR) and 11 were partial recovery (PR). Responsive rate was 45.80% (11/24) in patients with Ⅲ stage NSCLC and 25.00% (2/8) in patients with Ⅳ stage NSCLG respectively. The median survival time was 7.5 months. The one year survive rate was 65.63%. The main adverse effect was bone marrow depression. Conclusion Combination chemotherapy with docetaxel combined cisplatin in the treatment of Ⅲ- Ⅳ stage NSCLC has good clinical efficacy, light adverse effects and better tolerance, may be an effective and safe treatment for NSCLC. Key words: Docetaxel;  Cisplatin;  Combination chemotherapy;  Non small -cell lung cancer